RAGE RNAi Agent Subcutaneous Delivery via 2'-O-Methyl Modifications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNAi agents targeting the RAGE gene are not sufficiently potent or specific to be viable therapeutic options for treating RAGE-associated diseases.
Innovation Solution
Development of novel RAGE-specific RNAi agents with specific nucleotide sequences and chemical modifications, combined with targeting ligands for selective delivery to pulmonary epithelial cells, to achieve potent and efficient inhibition of RAGE gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current RNAi agents targeting the RAGE gene are used, then they can be administered to treat RAGE-associated diseases, but they are not sufficiently potent or specific to be viable therapeutic options
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the RNAi agent through specific 2'-O-methyl modifications at defined positions (e.g., positions 1-8 and 21-26 of the sense strand, and positions 1-7 and 20-26 of the antisense strand). These chemical parameter modifications enhance both the potency and specificity of the RNAi agent against the RAGE gene, resolving the contradiction between therapeutic viability and manufacturing precision by optimizing the molecular parameters of the therapeutic agent itself
2Productivity
If novel RAGE-specific RNAi agents with chemical modifications are developed, then potent and efficient inhibition of RAGE gene expression is achieved, but the complexity of the agent increases
Solution Approach 1:
The patent applies local quality by implementing selective 2'-O-methyl modifications at specific local positions (nucleotides 1-8 and 21-26 of the sense strand, and nucleotides 1-7 and 20-26 of the antisense strand) rather than uniform modification throughout the entire RNAi agent. This localized modification strategy enhances inhibition efficiency at critical regions while minimizing overall structural complexity, allowing the agent to maintain high productivity without excessive complexity
Solution Approach 2:
The patent creates a composite RNAi agent structure combining modified nucleotides (with 2'-O-methyl groups) and unmodified nucleotides in a specific pattern. This composite structure integrates the benefits of chemical modification (enhanced stability and potency) with the simplicity of natural RNA structures, achieving high inhibition efficiency while managing overall agent complexity through strategic composition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described RAGE RNAi agents demonstrate highly potent and efficient inhibition of RAGE gene expression, reducing receptor expression and associated inflammation, thereby providing a therapeutic benefit for various diseases mediated by RAGE.
Implementation Method 1
RNA interference (RNAi) agents, e.g., double stranded RNAi agents such as small (or short) interfering RNA
Implementation Method 2
The RNAi agent includes a sense strand and an antisense strand that are complementary to each other
Data Source
AI summary
Described are methods for subcutaneously administering a therapeutic composition comprising a RNAi agent for inhibiting Receptor for Advanced Glycation End-products (AGER or RAGE). The RAGE RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an AGER gene when administered subcutaneously. Pharmaceutical compositions that include one or more RAGE RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described RAGE RNAi agents to pulmonary cells, in vivo, provides for inhibition of AGER gene expression and a reduction in membrane RAGE activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as severe asthma. Subcutaneous delivery of the RAGE RNAi agents described herein can provide certain advantages over inhaled delivery.